International Journal of Molecular Sciences · مجلد 27 (20) · 9280-9280
There is growing interest in natural bioactive compounds as potentially safer and more sustainable sources of therapeutic agents. Terpenoids, one of the most structurally diverse and biologically active classes of natural products, are derived from repeating isoprene units and possess a broad range of pharmacological and industrial applications. This review provides a comprehensive overview of recent advances in terpenoid biosynthesis, structural classification, and therapeutic applications. It also discusses emerging approaches for enhancing large-scale production, improving functional efficacy, and overcoming pharmacokinetic limitations. Attention is given to terpenoids currently undergoing clinical evaluation, along with their progress toward commercial development. Despite substantial preclinical evidence supporting their therapeutic potential, the clinical translation of many terpenoids remains limited. Key challenges include poor aqueous solubility, low permeability, slow dissolution, and high lipophilicity, which can collectively restrict systemic bioavailability and therapeutic efficacy. Moreover, only a relatively small proportion of biologically active terpenoids have progressed to advanced stages of clinical development, highlighting a considerable gap between experimental findings and clinical application. This review integrates current knowledge of terpenoid biosynthesis, biological activities, production strategies, and translational development while highlighting sustainable and scientifically driven approaches that may facilitate their future therapeutic and commercial utilization.
Pea protein is gaining global attention as a sustainable, plant-based alternative to animal proteins due to its lower environmental impact. However, conventional thermal processing methods can degrade its functional and nutritional properties. This review explores sustainable non-thermal approaches for pea protein processing, focusing on pre-treatment, extraction, and modification. Ultrasonication is the most effective extraction technique and offers higher protein content (82.76 to 85.76%) compared to alkaline, air classification, and enzymatic methods. For protein modification, enzymatic treatment proves most effective, enhancing digestibility by 20.86 to 22.50% and solubility by 64.28 to 66.55%, while preserving structural integrity, compared to other non-thermal techniques. We critically assess the impact of these techniques on protein conformation, allergenicity reduction, and bioavailability and discuss their applications in food formulations and plant-based alternatives. Despite technological advances, significant research gaps remain in understanding molecular structural changes and challenges in industrial scalability. Future studies should focus on scaling processing methods.
pea proteinnon-thermal processingsonicationprotein extraction
Georgi. It has been recognized as an active phytochemical with specific therapeutic potential and significant pharmacological effects, especially in cancer research. Nevertheless, increasing preclinical data both in vitro and in vivo demonstrate its effectiveness against a broad spectrum of cancers, including breast, ovarian, lung, gastric, colorectal, prostate, renal, glioblastoma, and hematological types. Wogonin exerts its anticancer effects through a complex mechanism that involves the induction of programmed cell death (apoptosis), autophagic modulation, and cell cycle arrest. It also suppresses angiogenesis of tumors, epithelial-mesenchymal transition (EMT), invasion, metastasis, and multidrug resistance effects. The effects are supported by the compound's ability to regulate a variety of oncogenic and tumor-suppressive signaling pathways, particularly PI3K/Akt, STAT3, NF-kB, MAPK, AMPK, and Wnt/beta-catenin. It modulates apoptosis-related proteins (Bax, Bcl-2, PARP, caspases) and transcription factors. Wogonin has been shown to enhance the antitumor effects of established chemotherapeutic agents, and it works synergistically with these drugs in multiple cancer models, with the added benefits of reduced systemic toxicity. Nevertheless, it has poor oral bioavailability and water solubility, which limits its clinical application. Recent advances in nanocarriers and liposomal delivery systems show promise in overcoming pharmacokinetic challenges. This review consolidates available pharmacological, mechanistic, and pharmacokinetic evidence of wogonin, highlights its potential in combination therapies, and identifies research gaps and formulation strategies necessary for advancing this candidate towards clinical development as a novel anticancer agent.
The co-expression of epidermal growth factor receptor and carbonic anhydrase-IX in aggressive tumors such as triple-negative breast cancer contributes to therapeutic resistance through proliferative signaling and hypoxia-mediated adaptation. Dual inhibition of these targets represents a promising strategy for overcoming tumor resilience and enhancing treatment efficacy. A novel thiadiazole-based hybrid molecule ( N -(4-(( E )-1-((( Z )-5-acetyl-3-(4-sulfamoylphenyl)-1,3,4-thiadiazol-2(3 H )-ylidene)hydrazono)ethyl)phenyl)benzamide), ASTPB, was rationally designed through pharmacophore modeling, followed by molecular docking and molecular dynamics simulations for 200 ns to assess its dual-binding affinity to epidermal growth factor receptor and carbonic anhydrase-IX. Molecular dynamics simulations confirmed the stability of ASTPB complexes with both epidermal growth factor receptor and carbonic anhydrase-IX, as indicated by stable root mean square deviation values, consistent radius of gyration, and persistent hydrogen bonding, which supported its strong dual-binding affinity. Further quantum chemical analysis via density functional theory supported the electronic stability and reactive potential of ASTPB. In addition, in silico ADMET (Absorption, Distribution, Metabolism, Excretion, and toxicity) predictions indicated low toxicity, a wide safety margin, limited solubility and absorption, and overall favorable metabolic and distribution profiles. ASTPB was synthesized and exhibited potent dual inhibition of carbonic anhydrase-IX and epidermal growth factor receptor, with IC₅₀ values of 0.046 ± 0.007 µM and 0.059 ± 0.009 µM, respectively, comparable to standard inhibitors. In cytotoxicity assays, ASTPB was examined across several cancer cell lines (HePG-2, MCF-7, HCT-116, PC-3, MDA-MB-231), with the greatest efficacy against MDA-MB-231 (IC₅₀ = 18.15 µM) and minimal toxicity toward normal WI-38 cells (IC₅₀ = 72.46 µM). Cell cycle analysis revealed G0/G1 phase arrest, while Annexin V/PI staining indicated early apoptosis in 76.7% of cells. Molecular assays confirmed upregulation of Bax and caspase-3 (3.7-fold each) and downregulation of Bcl-2 (1.97-fold), indicating activation of the intrinsic apoptotic pathway. In conclusion, ASTPB is a promising dual carbonic anhydrase-IX/epidermal growth factor receptor inhibitor with selective cytotoxicity and potent pro-apoptotic activity, particularly in triple-negative breast cancer models. These findings support its potential as a multi-targeted therapeutic lead in the treatment of hypoxia-adapted, epidermal growth factor receptor–driven malignancies.
carbonic anhydrase IXepidermal growth factor receptortriple-negative breast cancerpharmacophore modeling
Lung inflammation is a hallmark of several respiratory diseases. Despite the great effectiveness of the synthetic antiinflammatory agents, they cause potential side effects. Polydatin (PD), a natural phytomedicine, has antioxidant and antiinflammatory effects. Its clinical applications are hindered due to poor aqueous solubility, low bioavailability, and rapid metabolism by first-pass effect. Herein, we report the development of a novel chitosan oligosaccharide-coated PD-loaded Poly dl-lactide-co-glycolide nanoparticles (COS-coated PD/PLGA NPs) against a bleomycin-induced pulmonary inflammation in a rat model. The NPs exhibited a small particle size of 188.57 ± 5.68 nm and a high zeta potential of + 18.13 ± 2.75 mV with spherical architecture and sustained release pattern of PD. In vivo studies in bleomycin-induced lung inflammation in a rat model revealed the superior prophylactic activity of COS-coated PD/PLGA NPs over the free drug (PD) as demonstrated by histopathological and immunohistochemical analyses, alongside biochemical assays evaluating oxidative stress biomarkers and inflammatory cytokine levels. Overall, the optimized COS-coated PD/PLGA NPs formulation offers a promising prophylactic platform against many respiratory diseases.
Gallic acid (GA) is a well-known herbal bioactive compound found in many herbs and foods like tea, wine, cashew nuts, hazelnuts, walnuts, plums, grapes, mangoes, blackberries, blueberries, and strawberries. GA has been reported for several pharmacological activities, such as antioxidant, inflammatory, antineoplastic, antimicrobial, etc. Apart from its incredible therapeutic benefits, it has been associated with low permeability and bioavailability issues, limiting their efficacy. GA belongs to BCS (Biopharmaceutics classification system) class III (high solubility and low probability). In this context, novel drug delivery approaches played a vital role in resolving these GA issues. Nanocarrier systems help improve drug moiety's physical and chemical stability by encapsulating them into a lipidic or polymeric matrix or core system. In this regard, researchers have developed a wide range of nanocarrier systems for GA, including liposomes, transfersomes, niosomes, dendrimers, phytosomes, micelles, nanoemulsions, metallic nanoparticles, solid lipid nanoparticles (SLNs), nanoparticles, nanostructured lipid carriers, polymer conjugates, etc. In the present review, different search engines like Scopus, PubMed, ScienceDirect, and Google Scholar have been referred to for acquiring recent information on the theme of the work. Therefore, this review paper aims to emphasize several novel drug delivery systems, patents, and clinical updates of GA.
Beilstein Journal of Nanotechnology · مجلد 15 · 1473-1497
Phytochemicals, naturally occurring compounds in plants, possess a wide range of therapeutic properties, including antioxidant, anti-inflammatory, anticancer, and antimicrobial activities. However, their clinical application is often hindered by poor water solubility, low bioavailability, rapid metabolism, and instability under physiological conditions. Polymer lipid hybrid nanoparticles (PLHNPs) have emerged as a novel delivery system that combines the advantages of both polymeric and lipid-based nanoparticles to overcome these challenges. This review explores the potential of PLHNPs to enhance the delivery and efficacy of phytochemicals for biomedical applications. We discuss the obstacles in the conventional delivery of phytochemicals, the fundamental architecture of PLHNPs, and the types of PLHNPs, highlighting their ability to improve encapsulation efficiency, stability, and controlled release of the encapsulated phytochemicals. In addition, the surface modification strategies to improve overall therapeutic efficacy by site-specific delivery of encapsulated phytochemicals are also discussed. Furthermore, we extensively discuss the preclinical studies on phytochemical encapsulated PLHNPs for the management of different diseases. Additionally, we explore the challenges ahead and prospects of PLHNPs regarding their widespread use in clinical settings. Overall, PLHNPs hold strong potential for the effective delivery of phytochemicals for biomedical applications. As per the findings from pre-clinical studies, this may offer a promising strategy for managing various diseases.
International Journal of Pharmaceutics X · مجلد 7 · 100232-100232
Diabetes mellitus (DM) is the most prevalent cause of diabetic retinopathy (DRP). DRP has been recognized for a long time as a microvascular disease. Many drugs were used to treat DRP, including vildagliptin (VLD). In addition to its hypoglycemic effect, VLD minimizes ocular inflammation and improves retinal blood flow for individuals with type 2 diabetes mellitus. Nevertheless, VLD can cause upper respiratory tract infections, diarrhea, nausea, hypoglycemia, and poor tolerability when taken orally regularly due to its high water solubility and permeability. Effective ocular administration of VLD is achieved using solid lipid nanoparticles (SLNPs), which improve corneal absorption, prolonged retention, and extended drug release. Ocuserts (OCUs) are sterile, long-acting ocular dosage forms that diminish the need for frequent dosing while improving residence time and stability. Therefore, this study intends to develop VLD solid lipid nanoparticle OCUs (VLD-SLNPs-OCUs) to circumvent the issues commonly associated with VLD. SLNPs were prepared using the double-emulsion/melt dispersion technique. The optimal formula has been implemented in OCUs. Optimization and development of VLD-SLNPs-OCUs were performed using a Box-Behnken Design (BBD). VLD-SLNPs-OCUs loading efficiency was 95.28 ± 2.87%, and differential scanning calorimetry data (DSC) showed the full transformation of VLD to an amorphous state and the excellent distribution in the prepared OCUs matrices. The in vivo release of VLD from the optimized OCUs after 24 h was 35.12 ± 2.47%, consistent with in vitro drug release data of 36.89 ± 3.11. The optimized OCUs are safe to use in the eye, as shown by the ocular irritation test. VLD-SLNPs-OCUs provide extended VLD release, an advantageous alternative to conventional oral dose forms, resulting in fewer systemic adverse effects and less variation in plasma drug levels. VLD-SLNPs-OCUs might benefit retinal microvascular blood flow beyond blood glucose control and may be considered a promising approach to treating diabetic retinopathy.
vildagliptinsolid lipid nanoparticlesOcusertocular drug delivery
Frontiers in Bioengineering and Biotechnology · مجلد 12 · 1454247-1454247
Ionic liquids (ILs) represent an exciting and promising solution for advancing drug delivery platforms. Their unique properties, including broad chemical diversity, adaptable structures, and exceptional thermal stability, make them ideal candidates for overcoming challenges in transdermal drug delivery. Despite encountering obstacles such as side reactions, impurity effects, biocompatibility concerns, and stability issues, ILs offer substantial potential in enhancing drug solubility, navigating physiological barriers, and improving particle stability. To propel the use of IL-based drug delivery in pharmaceutical innovation, it is imperative to devise new strategies and solvents that can amplify drug effectiveness, facilitate drug delivery to cells at the molecular level, and ensure compatibility with the human body. This review introduces innovative methods to effectively address the challenges associated with transdermal drug delivery, presenting progressive approaches to significantly improve the efficacy of this drug delivery system.
ionic liquidstransdermal drug deliveryskin permeationdrug solubility enhancement
Oral squamous cell carcinoma (OSCC) is a highly malignant and invasive tumor with significant mortality and morbidity. Current treatment modalities such as surgery, radiotherapy, and chemotherapy encounter significant limitations, such as poor targeting, systemic toxicity, and drug resistance. There is an urgent need for novel therapeutic strategies that offer targeted delivery, enhanced efficacy, and reduced side effects. The advent of lipid-based nanoparticles (LNPs) offers a promising tool for OSCC therapy, potentially overcoming the limitations of current therapeutic approaches. LNPs are composed of biodegradable and biocompatible lipids, which minimize the risk of toxicity and adverse effects. LNPs can encapsulate hydrophobic drugs, improving their solubility and stability in the biological environment, thereby enhancing their bioavailability. LNPs demonstrate significantly higher ability to encapsulate lipophilic drugs than other nanoparticle types. LNPs offer excellent storage stability, minimal drug leakage, and controlled drug release, making them highly effective nanoplatforms for the delivery of chemotherapeutic agents. Additionally, LNPs can be modified by complexing them with specific target ligands on their surface. This surface modification allows the active targeting of LNPs to the tumors in addition to the passive targeting mechanism. Furthermore, the PEGylation of LNPs improves their hydrophilicity and enhances their biological half-life by reducing clearance by the reticuloendothelial system. This review aims to discuss current treatment approaches and their limitations, as well as recent advancements in LNPs for better management of OSCC.
oral squamous cell carcinomalipid nanoparticlestargeted drug deliverychemotherapy
Disease-modifying anti-rheumatic drugs (DMARDs) is a class of anti-rheumatic medicines that are frequently prescribed to patients suffering from rheumatoid arthritis (RA). Methotrexate, sulfasalazine, hydroxychloroquine, and azathioprine are examples of non-biologic DMARDs that are being used for alleviating pain and preventing disease progression. Biologic DMARDs (bDMARDs) like infliximab, rituximab, etanercept, adalimumab, tocilizumab, certolizumab pegol, and abatacept have greater effectiveness with fewer adverse effects in comparison to non-biologic DMARDs. This review article delineates the classification of DMARDs and their characteristic attributes. The poor aqueous solubility or permeability causes the limited oral bioavailability of synthetic DMARDs, while the high molecular weights along with the bulky structures of bDMARDs have posed few obstacles in their drug delivery and need to be addressed through the development of nanoformulations like cubosomes, nanospheres, nanoemulsions, solid lipid nanoparticles, nanomicelles, liposome, niosomes, and nanostructured lipid carrier. The main focus of this review article is to highlight the potential role of nanotechnology in the drug delivery of DMARDs for increasing solubility, dissolution, and bioavailability for the improved management of RA. This article also focusses on the different aspects of nanoparticles like their applications in biologics, biocompatibility, body clearance, scalability, drug loading, and stability issues.
Prostate cancer is one of the most life-threatening disorders that occur in males. It has now become the third most common disease all over the world, and emerging cases and spiking mortality rates are becoming more challenging day by day. Several approaches have been used to treat prostate cancer, including surgery, radiation therapy, chemotherapy, etc. These are painful and invasive ways of treatment. Primarily, chemotherapy has been associated with numerous drawbacks restricting its further application. The majority of prostate cancers have the potential to become castration-resistant. Prostate cancer cells exhibit resistance to chemotherapy, resistance to radiation, ADT (androgen-deprivation therapy) resistance, and immune stiffness as a result of activating tumor-promoting signaling pathways and developing resistance to various treatment modalities. Nanomedicines such as liposomes, nanoparticles, branched dendrimers, carbon nanotubes, and quantum dots are promising disease management techniques in this context. Nanomedicines can target the drugs to the target site and enhance the drug's action for a prolonged period. They may also increase the solubility and bioavailability of poorly soluble drugs. This review summarizes the current data on nanomedicines for the prevention and treatment of prostate cancer. Thus, nanomedicine is pioneering in disease management.
The rise of antibiotic resistance underscores the urgent need for novel antibacterial agents. DNA gyrase, an essential enzyme involved in bacterial DNA replication, is a promising target for antibacterial therapy. Computational approaches offer a cost-effective means to design and screen potential inhibitors, such as eugenol derivatives. This study aims to computationally design eugenol derivatives as potential antibacterial agents targeting DNA gyrase, assess their binding affinities, evaluate physicochemical properties, and toxicity, and select lead compounds for further investigation. Molecular docking simulations were conducted to investigate the binding affinities of eugenol derivatives and controls to DNA gyrase. Physicochemical properties and toxicity assessments of eugenol were evaluated. Lead compounds were selected based on drug likeness, toxicity, and binding affinity. Molecular docking studies revealed varying binding affinities of eugenol derivatives to DNA gyrase, with lead compounds exhibiting superior affinity compared to eugenol. Physicochemical properties indicated moderate lipophilicity and low aqueous solubility for eugenol. Toxicity assessment revealed mutagenicity and tumorigenicity. De novo compound synthesis generated 244 novel compounds, with 44 selected based on drug-likeness, toxicity, and binding affinity as lead candidates. These findings provide valuable insights for the development of novel antibacterial agents targeting DNA gyrase, with implications for combating antibiotic resistance.
International Journal of Pharmacology · مجلد 20 (1) · 62-71
Background and Objective: Alzheimer’s disease (AD) is a severe, diverse and complex brain disorder that slowly degrades cognitive and memory abilities. Patients with a history of long-term use of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) have a lower risk of AD, according to epidemiological research. The objective of the research was to synthesize a novel dipeptide prodrug of ibuprofen and evaluate its anti-Alzheimer’s potential. Materials and Methods: A Novel Ibuprofen compound (Ibu-GLVL) was synthesized by the catalyst microwave method. Characterization of the compound was done by IR, 1[H] NMR and mass spectroscopy. The anti-Alzheimer’s activity was investigated using the Rotarod test and Morris water test against aluminum chloride-induced neurodegeneration. Further, histopathology was done on the hippocampus isolated from the experimental animals. Results: The characterization analysis predicted the composition of the novel compound as ‘C’-66.27%, ‘H’-8.34%, ‘N’-7.73% and ‘O’-17.66%. The solubility studies indicated that the R2 value was 0.9816, the compound was stable in both the pH of gastric and intestine and the partition coefficient (log P) value was 1.64. Further, the synthetic compound reduced significantly (p<0.05) the aluminum chloride defects using the rotarod and Morris-water test, which was confirmed with the histopathological examination. In vitro studies predicted that the newly synthesized compound inhibited the acetylcholinesterase activity. Conclusion: The data suggested that the newly synthesized prodrug form of ibuprofen is stable and could possess the potential to reduce the complications of AD. More research in this direction might aid in the discovery of a new therapeutic agent that has the potential to manage the symptoms of AD.
Frontiers in Pharmacology · مجلد 15 · 1494110-1494110
Breast carcinoma is one of the most frequent malignancies diagnosed globally and the chief cause of mortality among females (Siegel et al., 2021;Mir and Qayoom, 2023). Nearly 30% of all cancer incidences in women are due to breast cancer (Sung et al., 2021). Globally, BC represents recurrent malignancy among women. In 2020, it exceeded lung cancer to become the top reason of cancer incidence worldwide. A total of 2.3 million additional cases were anticipated, accounting for approximately 11.7% of all cancer cases (Hall et al., 1990).Epidemiological studies have revealed that the burden of breast cancer globally is thought to cross nearly 2 million by the year 2030 (Wooster et al., 1994). The primary major gene that was identified to be associated with hereditary BC in 1990 is BRCA1. Additionally, it was identified by employing linkage analysis in families by exploring suggestive pedigrees (Gallanis et al., 2021). Following this, BRCA2 was mapped to chromosome 13 in 1994 (Baldin et al., 1993). An alteration in either BRCA1 or BRCA2 increases susceptibility to cancer risk, especially BC. Metastatic breast cancer remains almost completely incurable, with an average overall survival (OS) of 3 years and a merely 25% 5-year OS (Cardoso et al., 2018;Sofi et al., 2022a).Although there have been significant advances in the strategies for curing breast cancer, the poor prognosis is still a matter of concern (Waks and Winer, 2019;Sofi et al., 2022b;Mir and Haq, 2023a;Qayoom et al., 2023a;Mir and Haq, 2023b). Due to its heterogeneous nature, it becomes hard to access the surviving individuals (Turashvili and Brogi, 2017;Mehraj et al., 2021;Qayoom et al., 2021). Multiple studies on breast cancer previously identified several genes which possess prognostic value. However, the developing field of bioinformatics along with advancing algorithms has provided researchers with the environment to discover potential genes by employing a different approach (Mehraj et al., 2022;Qayoom et al., 2023b;Sofi et al., 2023). The p53 protein has an essential role in prevention of genomic mutation in the body, but this protein is prone to mutations at a higher rate as witnessed in cancers. Moreover, a malfunction is witnessed in approximately all cancers along the p53 pathway. The altered p53 protein not only loses its function but is also susceptible to misfolding and accumulation, ultimately leading to the formation of amyloid aggregates. Protein misfolding and accumulation have a part to play in cancer development. Recognized as the "guardian of the genome," p53 plays a crucial role in preventing genomic mutations. Structurally, p53 represents a tetrameric transcription factor that modulates multiple cellular roles like expression of target genes that lead to apoptosis, repair of DNA, and arrest of the cell cycle in damaged cells in addition to cellular metabolism (Helton and Chen, 2007;Lukin et al., 2015;Mir et al., 2023a). Due to the fact that more than 50% of cancers are caused due to direct point mutations of p53 (Petitjean et al., 2007;Olivier et al., 2010) and the p53 malfunction as seen in aggressive cancer types like gastric cancer (Blanchet et al., 2021); thus, reverting or restoring the normal p53 function is a marked strategy for possible cancer cure (Hong et al., 2014;Bykov et al., 2018;Miller et al., 2020). The levels of P53 are highly modulated through posttranslational alterations and a pivotal modifier modulator mouse double minute 2 homolog (MDM2). However, during cellular stress, there is an inhibition to p53 degradation; in addition, the protein is accumulated in the nucleus (Friedman et al., 1993;Nag et al., 2013;Mir et al., 2022). The same causes target gene upregulation and triggers reaction mechanisms to bypass the multiplication of injured cells (Brooks and Gu, 2010). For example, when DNA damage occurs, p53 may either force the injured cell to be removed or trigger a cell cycle blockage mechanism that allows DNA repair to proceed (Helton and Chen, 2007;Lukin et al., 2015). The studies have revealed that the DNA-binding domain (DBD) of wild-type p53 displays less thermodynamic and kinetic stability (Natan et al., 2011) and several mutations lead to instability, ultimately causing protein unfolding. Cancer cells acquire high amounts of mutant p53 because it avoids the MDM2-mediated proteasomal destruction (Scian et al., 2004).MDM2 has been shown to play a post-ubiquitination function in the degradation of p53 (Kulikov et al., 2010). Aggregation and unfolding are intricate processes; however, destabilization exposes an adhesive sequence that attaches to the same section in other p53 units and triggers aggregation. Consequently, there is significant interest in the creation of novel agents that can both stabilize folded structures and prevent aggregation or split preformed aggregates (Miller et al., 2020;Miller et al., 2022). There are multiple ways through which altered p53 protein can be stabilized in its active and folded form. A comprehensive set of Michael acceptors, including CP-31398 and PRIMA1, has been seen to rectify the native information on mutant p53 and initiate p53-dependent cytotoxicity (Foster et al., 1999;Bykov et al., 2002;Rangel et al., 2019;Mir et al., 2023b). PhiKan-083 represents a small molecule and a carbazole derivative, which binds to the surface cavity and leads to the stabilization of a p53 mutant, namely, Y220C, possessing a Kd of 167 μM. Thus, we attempted to explore PhiKan-083 for breast cancer research. Y220C mutation, which is not involved in DNA interaction, causes a destabilization of the protein. PhiKan-083 binding stabilizes the mutant p53 and slows the rate of denaturation.Hence, for this study, we screened and examined many analogs of PhiKan-083 with better docking scores in comparison to PhiKan-083 for stabilizing misfolded p53. We evaluated the molecule-to-molecule docking of selected compounds to determine the therapeutic potential of screened PhiKan-083-related analogs by calculating the drug-likeliness of those compounds. This work identified two novel compounds that, in addition to their potential as PhiKan-083 substitutes, have advantages such as potential activity against a variety of p53-misfolded malignancies and not just breast cancer. We also looked at p53's expression patterns and predictive values across a range of cancer types, especially breast cancer.UALCAN (http://ualcan.path.uab.edu/) represents a web-based interactive portal to investigate cancer omics data (Chandrashekar et al., 2017). UALCAN has been made to furnish access to publicly available cancer OMICS data easily with the aim of running in silico validation of genes that are of interest or to identify related biomarkers. These databases furnish the graphical representation along with the plots displaying the expression profiles along with the subject survival information. We selected TCGA invasive breast carcinoma data, and P53 expression was examined among different cancer stages, sample types, and sub-classes.TIMER 2.0 (http://timer.comp-genomics.org/) is an instructive tool used to thoroughly evaluate the expression and quantification of immune infiltrates across malignancies. Users can investigate the connection between gene expression and other variables using the database's algorithms, including quanTIseq, CIBERSORT, MCPcounter, and EPIC algorithms; the status of its mutation; and its association with different immune cell kinds. To better comprehend the gene expression profiles of all malignancies, a heatmap of TP53 was created using TIMER 2.0 (Li et al., 2020).Through TCGA and GTEx projects, RNA-sequencing expression data from 9,736 tumors and 8,587 normal samples were analyzed using the web-based application GEPIA2 (http://gepia2.cancer-pku.cn). Subject survival analysis, dimensionality reduction study, identification of related genes, profiling based on cancer types or pathological stages, assessment of differential expression between tumors and normal tissues, and correlation analysis are a few of the resources that can be tailored. By gathering RNA-seq datasets from the UCSC Xena project (http://xena.ucsc.edu), the GEPIA2 followed a pre-established process (Tang et al., 2019). The TP53 expression in varied cancers was obtained by employing the GEPIA2 portal.The breast cancer gene-expressionminer v4.5 (http://bcgenex.ico.unicancer.fr/) is a bioinformatics tool available online that contains published BC transcriptomic and RNA-seq data in an annotated form (Jézéquel et al., 2012;Jezequel et al., 2013). It was employed to analyze the link between p53 expression levels and distinct clinical factors of breast tumor subjects. P53 expression analysis results were analyzed for basal-like luminal A and luminal B types.For researchers who want to carefully examine the functional proteomics of various cancer types, the University of Texas MD Anderson Cancer Center's Cancer Proteome Atlas Portal is a goto source (https://tcpaportal.org/tcpa/). Using the website's database of patient cohorts, the users can search through the datasets of patient tumors that have been obtained and sequenced by the Center. Users can obtain thorough explanations of each dataset and use a network model or heatmap to evaluate the interactions of the proteins in the data. This website offers a database of cancer cell lines in addition to the patient's cohort database, which researchers can browse and analyze.The National Human Genome Research Institute (NHGRI) and the National Cancer Institute (NCI), both of which are divisions of the National Institutes of Health of the U.S. Department of Health and Human Services, have collaborated on it (https://portal.gdc.cancer.gov/). A pilot study for the Cancer Genome Atlas was conducted to see whether a larger project must be undertaken to systematically examine every type of genetic mutation connected to human cancer. Next, using matched normal samples, the scientists molecularly defined almost 20,000 initial cancer samples from 33 distinct cancer types. It is open to all members of the scientific community to use the almost 2.5 petabytes of data generated by TCGA.Since 1992, PredictProtein (https://predictprotein.org) has predicted the structure and functional characteristics of proteins using sequence analysis. Multiple sequence alignments anticipated structural elements [solvent accessibility, secondary structure, coiled-coil regions, transmembrane helices (TMSEG) and strands, disulfide bonds, and disordered areas] and functional elements are returned in response to a protein sequence query. Among the analysis techniques included in the service are functional region identification (ConSurf), homologybased inference of GO terms (meta-student), precise subcellular localization prediction (LocTree3), protein-polynucleotide binding sites (SomeNA), protein-polynucleotide binding sites (ISIS2), and predictions of the impact of point mutations (non-synonymous SNPs) on protein function (SNAP2). Their objective has consistently been to provide a tailored solution that satisfies the needs of researchers with less experience in bioinformatics. To achieve this, the PredictProtein results are given as text along with a number of coherent, engaging, and visually appealing images. The sources and web server may be accessed at (http://ppopen.rostlab.org).In this work, PhiKan-083 served as the reference compound, and 100 compounds with similar structural properties were examined. We collected these compounds from the PubChem database (https://pubchem.ncbi.nlm.nih.gov/) and investigated all of the physico-chemical characteristics of the compounds. The specific compounds were analyzed using Discovery Studio v18 after copying them in SDF format (Kim et al., 2019).The retrieved PhiKan-083 analogues were assessed for drug-likeness using Swiss ADME, an online portal that assesses a drug's potential by examining characteristics such as Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) of the selected 100 analogues (http://www.swissadme.ch). Numerous parameters, such as hydrogen bond acceptors (nHBAs), the log of the n-octanol/water partition coefficient (LogP), hydrogen bond donors (nHBDs), molecular polar surface area (PSA), molecular weight (MW), and number of rotatable bonds (nRotBs), were calculated by incorporating Lipinski's rule of five and the Veber rule. The ADMET prediction technique took into account a number of parameters, including aqueous solubility, cytochrome P450 (CYP) 2D6 inhibition, hepatotoxicity, intestinal absorption, and plasma protein binding. After being chosen, the compounds that complied with ADMET drug likeliness guidelines underwent molecular docking (Rudrapal et al., 2022).The target protein TP53 (PDB ID 8dc4) was obtained from the Protein Data Bank (PDB) in a PDB format (Kulikov et al., 2010). By removing the extra structural moieties like heteroatoms, water molecules, and any associated ligands, the p53 protein was cleared up for further study using the Discovery studio (Nguyen et al., 2014).To ascertain the ligands' affinities for binding to TP53, the compounds were first exposed to molecular docking after undergoing ADMET analysis. Every ligand was docked with the TP53 protein using Auto Dock v4.2.6. Using the co-crystallized X-ray structure of the p53 protein from the RCSB PDB, the binding cavity was built. The co-crystallized ligand's three spacers' residue locations were computed. Following the selection of a cavity, the energy was reduced by applying conjugate gradient and steepest descent algorithms. By merging the nonpolar hydrogens, the receptor and target molecules were finally stored in pdbqt format. We created grid boxes at 0.3 intervals. The protein-ligand complex was docked using the Lamarckian Genetic Algorithm (LGA) in order to determine the lowest free energy of binding (G). Three similar sets of molecular modeling experiments were carried out, with the default settings being a maximum of 2700 generations, 2,500,000 evaluations, and 50 solutions each set (Qayoom et al., 2022).As shown in the heatmap in Figure 1 A, the TIMER 2.0 analysis of the TP53 expression pattern showed overexpression of TP53 across all TCGA datasets. TP53 levels were further assessed using CPTAC samples from the UALCAN database. When compared to normal samples, it was also discovered that the levels of the protein TP53 were significantly raised in a number Using the web-based Enrichr programme for GO analysis, it was demonstrated that MF was considerably enriched compared to BP and CC. The Figure 3 Using KM-plotter from GEPIA2, the prognostic significance of TP53 was assessed across all cancer types. The relationship between overall survival (OS) and relapse-free survival (RFS) and the median expression of TP53 was investigated. According to the study, reduced overall survival (OS) is associated with elevated TP53 expression in the ACC, BRCA, KIRP, LAML,LGG, LIHC, PRAD, SARC, THCA, and UCS Figure 4. The hazard ratio for all malignancies ranged from 1 to 12, with LIHC having the lowest and PRAD having the highest. High TP53 mRNA levels are linked to worse relapse-free survival (RFS) in LGG, UCS, and BRCA, followed by LAML, SARC, ACC, KIRP, LIHC, PRAD, and THCA according to the connection between TP53 mRNA levels and RFS. These investigations demonstrated the importance of TP53 in cancer prognosis, making it a promising target for treating various malignancies. Using UALCAN database, we analyzed the expression pattern of p53 in breast cancer. The heat map was generated by correlating p53 with other overexpressed genes in BC using correlation coefficient The study showed that among all the genes, p53 was We compared the p53 expression in both normal and tumor samples, p53 was in breast cancer. Using the same database, we also analyzed the expression of p53 among various of BC the major associated with p53 misfolding is due to its point mutation we the sequence of P53 using database to the of the status of It was revealed that p53 protein sequence has higher of structural mutations that have significantly its its tumor protein misfolding is it was further assessed to the of mutations that are or mutations that lead to of tumor It was seen that protein misfolding to the of function potential of P53 protein as is shown in the Figure was revealed from the results that P53 protein expression was highly in several cancers including breast cancer and the misfolding was to its of function tumor development. We further the protein secondary structure using the tool and the functional of point mutations of p53 protein and the of it by a heatmap using as shown in Figure for its potential and higher of cases due to the same In order to 100 molecules that are similar to the PubChem database was Following that, the compounds were examined ADMET analysis. compounds specific drug-likeliness characteristics were from the screened including PhiKan-083 as in Using molecular docking the binding of these compounds with TP53 was further Following ADMET each drug underwent a molecular docking study with the target TP53 activity of the was from the binding of the compounds. According to the study, two with the PubChem and higher binding compared to the reference molecule The TIMER 2.0 analysis of the TP53 expression pattern revealed overexpression of TP53 across all TCGA datasets. TP53 levels were further assessed using CPTAC samples from the UALCAN database. After with normal samples, it was also witnessed that the levels of TP53 protein were significantly elevated in various tumor GEPIA2 database, we further examined the expression pattern of TP53 in several malignancies. These results that TP53 is highly in several malignancies, including BRCA, luminal A, luminal and the it was witnessed that MF was significantly enriched in comparison to BP and through GO analysis. By employing KM-plotter from GEPIA2, the prognostic importance of TP53 was assessed across all cancer types. the study, reduced overall survival (OS) was linked with TP53 expression in the ACC, BRCA, KIRP, LAML, LGG, LIHC, PRAD, SARC, THCA, and TP53 mRNA levels were to worse relapse-free survival (RFS) in LGG, UCS, and BRCA, followed by LAML, SARC, ACC, KIRP, LIHC, PRAD, and THCA as the link between TP53 mRNA levels and RFS. These investigations demonstrated the significance of TP53 in cancer prognosis, it as a promising target for treating various malignancies. UALCAN database, we analyzed the expression pattern of p53 in breast cancer. is the most aggressive of breast cancer, study revealed that among all P53 was in and it was most in the major associated with p53 misfolding is due to its point mutation we examined the sequence of P53 using database to the of the status of It was that protein misfolding to the of function potential of P53 protein. We further the protein secondary structure by exploring the web-based PredictProtein tool and examined the functional of point mutations of p53 protein and its by a heatmap using In order to analyze the 100 molecules that are similar to the PubChem database was Following this, the same compounds were analyzed through ADMET analysis. The top compounds specific drug-likeliness characteristics were from the screened including PhiKan-083 by using the molecular docking the binding of these compounds with TP53 was the we to explore the expression of TP53 in its therapeutic prognostic and the impact of overexpression on overall and relapse-free survival in a range of cancers. We the TP53 expression profiles across all TCGA using the TIMER 2.0 database. When TP53 was compared to normal samples for study of differential it was shown that malignancies such BRCA, and elevated TP53 According to this study, TP53 is a major in a number of making it a TP53 overexpression was shown to be caused by gene alteration and TCGA analysis was used to evaluate this examining the correlation between mRNA expression and survival demonstrated a significant association with many malignancies with elevated hazard study a correlation between high TP53 mRNA levels and poor OS in ACC, BRCA, KIRP, LAML, LGG, LIHC, PRAD, SARC, THCA, and free survival (RFS) has been associated with higher TP53 mRNA levels in KIRP, LIHC, and we the impact of point mutations on p53 protein misfolding using database. The of genetic alteration a role in of of P53 protein. we examined the potential role of a P53 stabilizing and its analogues in breast cancer. We screened 100 analogues to PhiKan-083 and examined them for their drug-likeliness Among those compounds were selected for their drug-likeliness and further investigated molecular docking We two novel compounds and analogues to PhiKan-083 that may be further for their therapeutic potential by P53 misfolding not only for breast cancer but for other as